Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Day (June 2018)
34 slides from Astrazeneca's investor day presentation, Jun 4, 2018
Slide 1: ASCO 2018 investor event: a leading, diversified oncology business
Hyatt Conference Columbus2018 ASCO 2018 investor event: a leading, diversified oncology business Chicago, Illinois, USA 04 June 2018
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, pe
Slide 3: Presenters and break-out sessions
Presenters Pascal Soriot Dave Fredrickson Klaus Edvardsen Susan Galbraith Break-out sessions Executive Director and Executive Vice President, Senior Vice President, Senior Vice President, Chief Executive Officer Oncology Business Unit Head of Oncology, GMD Head of Oncology, IMED Biotech Unit David B
Slide 4: Agenda
Agenda AstraZeneca Oncology Key data at ASCO 2018 Annual Meeting Break-out sessions ~19:45 - 1st set of four concurrent breakout sessions + Q&A (30 minutes) 10 minutes break to allow for room changes ~20:25 - 2nd set of four concurrent breakout sessions + Q&A (30 minutes) ~21:00 - End Break-out sess
Slide 5: AstraZeneca: a leading, diversified oncology business
AstraZeneca: a leading, diversified oncology business New medicines grew 122% in Q1 2018; a solid lifecycle to follow Multiple cancers Lung cancers Blood cancers • Ovarian and breast • Stage IV 2nd line • Unresectable Stage III • First AstraZeneca cancers T790Mm1 moving to NSCLC3 medicine in blood c
Slide 6: Lynparza: the leading PARP inhibitor across multiple tumour types
Lynparza The leading PARP inhibitor across multiple tumour types Product Sales Lifecycle opportunities have ~18 $m Q1 2018: 100% growth significant growth potential 140 bevacizumab (VEGF) combo PAOLA-1 120 Potential launches1 Data 2019 cediranib 100 (VEGFr2) combo Data 2019 Early breast 1st line can
Slide 7: Lung cancers: Tagrisso
Lung cancers: Tagrisso Expanding patient benefits into earlier lines of treatment Product Sales Now expanding into the With Stage I-III (adjuvant) $m Q1 2018: 89% growth Stage IV 1st-line setting as a future opportunity 400 Wild type ALKm 1 EGFRm 350 ADAURA Phase III trial Up to 3 years 300 250 ~370
Slide 8: Lung cancers: Imfinzi
Lung cancers: Imfinzi First and only in early lung cancer; now with proven survival The strong US uptake Significant unmet need in Imfinzi in early reflects patient benefit unresectable, Stage III lung cancer Resectable Unresectable • PACIFIC OS announced 25 April 8,000 • PACIFIC-2 concurrent trial
Slide 9: Lung cancers: Imfinzi, Stage III last chance for curative treatment
Lung cancers: Imfinzi Stage III: last chance for treatment with curative intent Lung cancer patients at diagnosis (%) Five-year survival rates by stage Stage I 27% 100% Early stage 80% 79% Stage II 11% 60% 66% 40% Stage III 25% 20% 15% 6% Metastatic 0% 0 24 48 72 Stage IV 37% Months Sources: Maione
Slide 10: Haematology: Calquence and moxetumomab
Haematology: Calquence and moxetumomab Emerging franchise; initially in smaller indications Calquence Moxetumomab Best-in-class BTK inhibitor in MCL Development plans pasudotox Launched in the • First AstraZeneca/MedImmune US in R/R1 MCL immunotoxin • Under US priority regulatory Phase IB/II WM2 ✓✓
Slide 11: Oncology: industry-leading pipeline
Oncology: industry-leading pipeline Rich and deep pipeline across Phase I-III Includes significant lifecycle management projects and parallel indications for projects in Phase III or beyond. Excludes lifecycle management projects already launched in a major market. # Partnered and/or in collaboratio
Slide 12: Agenda
Agenda AstraZeneca Oncology Key data at ASCO 2018 Annual Meeting Break-out sessions ~19:45 - 1st set of four concurrent breakout sessions + Q&A (30 minutes) 10 minutes break to allow for room changes ~20:25 - 2nd set of four concurrent breakout sessions + Q&A (30 minutes) ~21:00 - End Break-out sess
Slide 13: AstraZeneca at ASCO 2018 Annual Meeting
AstraZeneca at ASCO 2018 Annual Meeting Increasing quality; more oral presentations and poster discussions Abstract scorecard Highlights 74% • Lynparza 2018 10% 91 Seven Study 08 randomised Phase II trial in prostate cancer ‘Best of ASCO’ presentations 16% • moxetumomab pasudotox Study ’1053’ Phase
Slide 14: Lynparza: Prostate cancer - Study 08 - trial design
Lynparza Prostate cancer - Study 08 - trial design 14
Slide 15: Lynparza: Prostate cancer - Study 08 - primary endpoint (rPFS)
Lynparza Prostate cancer - Study 08 - primary endpoint (rPFS) 15
Slide 16: Lynparza: Prostate cancer - Study 08 - safety summary
Lynparza Prostate cancer - Study 08 - safety summary 16
Slide 17: Lynparza: Prostate cancer - Study 08 - conclusions
Lynparza Prostate cancer - Study 08 - conclusions 17
Slide 18: Moxetumomab pasudotox: Study 1053 - introduction
Moxetumomab pasudotox Hairy cell leukaemia 3rd line+ - Study ‘1053’ - introduction 18
Slide 19: Moxetumomab pasudotox: Study 1053 - trial design
Moxetumomab pasudotox Hairy cell leukaemia 3rd line+ - Study ‘1053’ - trial design 19
Slide 20: Moxetumomab pasudotox: Study 1053 - patient disposition
Moxetumomab pasudotox Hairy cell leukaemia 3rd line+ - Study ‘1053’ - patient disposition 20
Slide 21: Moxetumomab pasudotox: Study 1053 - primary endpoint (CR)
Moxetumomab pasudotox Hairy cell leukaemia 3rd line+ - Study ‘1053’ - primary endpoint (CR) 21
Slide 22: Moxetumomab pasudotox: Study 1053 - duration of response
Moxetumomab pasudotox Hairy cell leukaemia 3rd line+ - Study ‘1053’ - duration of response 22
Slide 23: Moxetumomab pasudotox: Study 1053 - safety summary
Moxetumomab pasudotox Hairy cell leukaemia 3rd line+ - Study ‘1053’ - safety summary 23
Slide 24: Moxetumomab pasudotox: Study 1053 - safety summary
Moxetumomab pasudotox Hairy cell leukaemia 3rd line+ - Study ‘1053’ - safety summary 24
Slide 25: Moxetumomab pasudotox: Study 1053 - conclusions
Moxetumomab pasudotox Hairy cell leukaemia 3rd line+ - Study ‘1053’ - conclusions 25
Slide 26: Selumetinib: NF-1 - disease explanation
Selumetinib NF-1 - disease explanation Neurofibromatosis type 1 (NF-1) is an incurable genetic condition that can cause tumours to form in the nervous system, including the brain, spinal cord and nerves. In many cases, careful monitoring and treatment can help people 15 with NF-1 live a full life. H
Slide 27: Selumetinib: NF-1 - SPRINT trial - trial overview
Selumetinib NF-1 - SPRINT trial - trial overview
Slide 28: Selumetinib: NF-1 - SPRINT trial - primary endpoint (PR)
Selumetinib NF-1 - SPRINT trial - primary endpoint (PR)
Slide 29: Selumetinib: NF-1 - SPRINT trial - safety summary
Selumetinib NF-1 - SPRINT trial - safety summary 29
Slide 30: Selumetinib: NF-1 - SPRINT trial - conclusions
Selumetinib NF-1 - SPRINT trial - conclusions 30
Slide 31: Other highlights
Other highlights Additional key data; details available in break-out sessions DNA damage Immuno- Tumour drivers response Oncology Haematology Imfinzi NSCLC Stage IV 3rd line - Phase II Lynparza + Imfinzi ATLANTIC trial capivasertib vistusertib unresectable Stage III (updated results) (AZD5363, (AZD2
Slide 32: Agenda
Agenda AstraZeneca Oncology Key data at ASCO 2018 Annual Meeting Break-out sessions ~19:45 - 1st set of four concurrent breakout sessions + Q&A (30 minutes) 10 minutes break to allow for room changes ~20:25 - 2nd set of four concurrent breakout sessions + Q&A (30 minutes) ~21:00 - End Break-out sess
Slide 33: Break-out sessions
Break-out sessions Each session will run twice; 19:45 and 20:25 Session 1 in Session 2 in Columbus G Columbus H Sales & Marketing Lynparza lifecycle; execution MRK collaboration Host: Dave Fredrickson Host: Klaus Edvardsen Main Session 3 in Session 4 in room Columbus I/J Columbus K/L Break- Next-gen
Slide 34: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non- commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availab